Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.50 |
| ▸ | CTSG | P08311 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528481 | 1.00 | FAAH (0.56) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL5550460 | 1.00 | FAAH (0.56) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL29235949 | 0.92 | FAAH (0.51) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL29114311 | 0.92 | FAAH (0.51) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL17003656 | 0.91 | FAAH (0.50) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL20787950 | 0.91 | FAAH (0.50) | FAAHGSK3AGSK3BEPHX2PTGS1 | |
| SCHEMBL27057602 | 0.91 | HDAC3 (0.51) | FAAHGSK3AGSK3BPTGS1PTGS2 | |
| Lysine SCHEMBL6259867 | 0.88 | ITGB3 (0.50) | FAAHEPHX2 | |
| SCHEMBL31421913 | 0.87 | GSK3A (0.48) | FAAHGSK3AGSK3BEPHX2ACE | |
| SCHEMBL16847778 | 0.87 | ALDH1A1 (0.65) | FAAHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718340-B1 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-11-21 | — | — | EP | disclosed |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | FAAH 4508/4885GSK3A 3687/4885GSK3B 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.